Paper36974661
Current Advances and Future Prospects in Cancer Immunotherapeutics.
Dede Z and 3 others. Medeni Med J, 2023. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Current Advances and Future Prospects in Cancer Immunotherapeutics. Papers, record 36974661. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36974661
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27000871 | Advances in personalized cancer immunotherapy. | Breast Cancer | 2017 | https://conductscience.org/library/papers/27000871 | PubMed |
| 2 | 33818764 | Cancer statistics for the year 2020: An overview. | Int J Cancer | 2021 | https://conductscience.org/library/papers/33818764 | PubMed |
| 3 | 33921028 | mRNA-Based Vaccines. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/33921028 | PubMed |
| 4 | 33859752 | Turning cold tumors into hot tumors by improving T-cell infiltration. | Theranostics | 2021 | https://conductscience.org/library/papers/33859752 | PubMed |
| 5 | 27930631 | CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. | Clin Adv Hematol Oncol | 2016 | https://conductscience.org/library/papers/27930631 | PubMed |
| 6 | 31715131 | Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. | Cancer Cell | 2019 | https://conductscience.org/library/papers/31715131 | PubMed |
| 7 | 22258609 | Clonal evolution in cancer. | Nature | 2012 | https://conductscience.org/library/papers/22258609 | PubMed |
| 8 | 32698317 | Monoclonal Antibodies in Cancer Therapy. | Antibodies (Basel) | 2020 | https://conductscience.org/library/papers/32698317 | PubMed |
| 9 | 22190859 | Tumor evasion from T cell surveillance. | J Biomed Biotechnol | 2011 | https://conductscience.org/library/papers/22190859 | PubMed |
| 10 | 33745426 | The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer. | Endocr Metab Immune Disord Drug Targets | 2021 | https://conductscience.org/library/papers/33745426 | PubMed |
| 11 | 35110735 | Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. | Nature | 2022 | https://conductscience.org/library/papers/35110735 | PubMed |
| 12 | 34522017 | The tangled history of mRNA vaccines. | Nature | 2021 | https://conductscience.org/library/papers/34522017 | PubMed |
| 13 | 21074069 | Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. | Semin Oncol | 2010 | https://conductscience.org/library/papers/21074069 | PubMed |
| 14 | 33907315 | Therapeutic cancer vaccines. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/33907315 | PubMed |
| 15 | 28416815 | In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. | Nat Nanotechnol | 2017 | https://conductscience.org/library/papers/28416815 | PubMed |
| 16 | 35569432 | Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. | Int Immunopharmacol | 2022 | https://conductscience.org/library/papers/35569432 | PubMed |
| 17 | 30539464 | Human Monoclonal Antibodies: The Benefits of Humanization. | Methods Mol Biol | 2019 | https://conductscience.org/library/papers/30539464 | PubMed |
| 18 | 33859638 | Cancer Vaccines, Adjuvants, and Delivery Systems. | Front Immunol | 2021 | https://conductscience.org/library/papers/33859638 | PubMed |
| 19 | 31754328 | Current Progress in CAR-T Cell Therapy for Solid Tumors. | Int J Biol Sci | 2019 | https://conductscience.org/library/papers/31754328 | PubMed |
| 20 | 35020204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42515758 | Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42515758 | PubMed |
| 41285444 | Variations in Cancer with Heart Failure Related Mortality in the United States from 1999-2020. | Clin Med Res | 2025 | https://conductscience.org/library/papers/41285444 | PubMed |
| 40059555 | "I Became the Messenger Between the Hospitals": A Study on the Journeys of People With Cancer Using the Critical Incident Technique. | Health Expect | 2025 | https://conductscience.org/library/papers/40059555 | PubMed |
| 39729909 | Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer. | Redox Biol | 2025 | https://conductscience.org/library/papers/39729909 | PubMed |
| 39519237 | GdVO4:Eu3+ and LaVO4:Eu3+ Nanoparticles Exacerbate Oxidative Stress in L929 Cells: Potential Implications for Cancer Therapy. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39519237 | PubMed |
| 39311156 | Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development. | Med Sci (Basel) | 2024 | https://conductscience.org/library/papers/39311156 | PubMed |
| 38853541 | Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy. | Cancer Res Treat | 2025 | https://conductscience.org/library/papers/38853541 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36974661
GET https://conductscience.org/api/papers/v1/36974661/references?page=2